Actavis (ACT), Gedeon Richter Report FDA Receipt of Antipsychotic Cariprazine Resubmission
Tweet Send to a Friend
Actavis (NYSE: ACT) and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
